ConductScience.org, home

Comparison · NCT04152161-b16b7473

Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Serious Adverse Drug Reactions (ADRs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Serious Adverse Drug Reactions (ADRs). Trial comparisons, record NCT04152161-b16b7473. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04152161-b16b7473

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00417wilson
Risk in group 2000.00417wilson
Risk difference, group 1 minus group 20-0.004170.00417newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Bacille Calmette Guerin (BCG) GroupParticipants were randomized to receive a single 0.1 mL volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.0918OG000
Group 2Placebo GroupParticipants were randomized to receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.0917OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Serious Adverse Drug Reactions (ADRs)
Description
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. When an AE is judged to be serious and related to an investigational product, it is a Serious ADR.
Time frame
Up to 48 months
Population
Safety Population

Source ClinicalTrials.gov

Trial

Title
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection
NCT number
NCT04152161
Phases
PHASE2
Conditions
Tuberculosis
Interventions
BCG vaccine SSI, Placebo
Lead sponsor
Gates Medical Research Institute
Results first posted
2025-06-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04152161-b16b7473